Essex Investment Management Co. LLC bought a new stake in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 474,955 shares of the company's stock, valued at approximately $1,610,000. Essex Investment Management Co. LLC owned 0.32% of Xeris Biopharma as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds also recently modified their holdings of XERS. R Squared Ltd acquired a new position in Xeris Biopharma during the fourth quarter valued at approximately $42,000. Wealth Enhancement Advisory Services LLC acquired a new position in shares of Xeris Biopharma during the 3rd quarter worth $35,000. Raymond James Financial Inc. acquired a new position in shares of Xeris Biopharma during the 4th quarter worth $45,000. Quantbot Technologies LP acquired a new stake in Xeris Biopharma in the third quarter valued at about $44,000. Finally, Sunpointe LLC bought a new position in Xeris Biopharma in the fourth quarter valued at about $71,000. Institutional investors own 42.75% of the company's stock.
Xeris Biopharma Trading Down 0.2 %
Xeris Biopharma stock traded down $0.01 during midday trading on Thursday, reaching $4.56. The stock had a trading volume of 2,559,176 shares, compared to its average volume of 2,129,065. The company has a fifty day moving average price of $3.64 and a two-hundred day moving average price of $3.29. The company has a market capitalization of $679.81 million, a P/E ratio of -10.13 and a beta of 2.32. Xeris Biopharma Holdings, Inc. has a 12 month low of $1.69 and a 12 month high of $4.68.
Wall Street Analyst Weigh In
A number of research firms have recently commented on XERS. Leerink Partners increased their target price on shares of Xeris Biopharma from $5.00 to $6.00 and gave the stock an "outperform" rating in a report on Friday, March 7th. Piper Sandler reissued a "neutral" rating and issued a $4.00 price objective (up previously from $3.00) on shares of Xeris Biopharma in a research note on Friday, March 7th. Jefferies Financial Group reaffirmed a "buy" rating and set a $6.00 target price (up previously from $4.00) on shares of Xeris Biopharma in a research note on Wednesday, January 29th. Craig Hallum raised their price objective on Xeris Biopharma from $5.00 to $6.50 and gave the company a "buy" rating in a report on Friday, March 7th. Finally, HC Wainwright restated a "buy" rating and set a $8.00 price objective (up previously from $6.60) on shares of Xeris Biopharma in a research report on Friday, March 7th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $5.92.
Read Our Latest Research Report on Xeris Biopharma
About Xeris Biopharma
(
Free Report)
Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.
Featured Stories
Before you consider Xeris Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xeris Biopharma wasn't on the list.
While Xeris Biopharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market volatility creates opportunity. Our analysts have pinpointed 10 stocks perfectly positioned for exceptional growth this spring, even amid economic uncertainty. Don't miss your chance to access this timely research and invest with confidence.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
